VistaGen Therapeutics
VTGN
48 hedge funds and large institutions have $39M invested in VistaGen Therapeutics in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 12 increasing their positions, 20 reducing their positions, and 9 closing their positions.
625% more call options, than puts
Call options by funds: $29K | Put options by funds: $4K
0.51% less ownership
Funds ownership: 55.75% → 55.24% (-0.51%)
11% less funds holding
Funds holding: 54 → 48 (-6)
13% less capital invested
Capital invested by funds: $44.9M → $39M (-$5.83M)
40% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 20
67% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.48M |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$847K |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$440K |
| 4 |
DP
Diadema Partners
Morristown,
New Jersey
|
+$349K |
| 5 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$168K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$574K |
| 2 |
Squarepoint
New York
|
-$318K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$302K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$261K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$170K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LCM
51
Landscape Capital Management
Englewood,
New Jersey
| – | -$123K | -41,804 | Closed |
|
52
Millennium Management
New York
| – | -$114K | -38,732 | Closed |
|
53
Man Group
London,
United Kingdom
| – | -$54.1K | -18,338 | Closed |
|
|
RS
54
R Squared
Central,
Hong Kong
| – | -$25.4K | -8,610 | Closed |
|
|
CM
55
Caption Management
Oklahoma City,
Oklahoma
| – | -$13.2K | -4,460 | Closed |
|
|
BL
56
BFSG LLC
Irvine,
California
| – | -$2.95K | -1,000 | Closed |
|
|
TRCT
57
Tower Research Capital (TRC)
New York
| – | -$658 | -223 | Closed |
|
VTGN Hedge Fund Activity: Q1 2025 in Review
48 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q1 2025, worth a combined $39M — down 13% from $44.9M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of VTGN and 3 opened new positions — a net loss of 6 holders — while 20 trimmed existing stakes and 12 added.
The largest buyer was Ikarian Capital, adding an estimated $1.48M. The largest seller was Goldman Sachs, exiting entirely with an estimated $574K sold.
- 48 institutional investors held VistaGen Therapeutics (VTGN) as of Q1 2025, down from 54 in Q4 2024.
- Funds reported $39M of VistaGen Therapeutics stock for Q1 2025, down 13% quarter-over-quarter.
- 3 funds opened new VistaGen Therapeutics positions in Q1 2025 and 9 closed out, a net change of -6 holders.
- The largest VistaGen Therapeutics buyer in Q1 2025 was Ikarian Capital, an estimated $1.48M added.
- The largest VistaGen Therapeutics seller in Q1 2025 was Goldman Sachs, an estimated $574K sold.
Based on aggregated 13F filings for Q1 2025.